Improving the care pathway for patients with respiratory failure. Biosency aims to improve the management of patients with cardio-respiratory insufficiency by offering a disruptive digital solution, integrating clinical data analysis, to optimise monitoring and facilitate coordination between health professionals.
Oxygen titration aid Carrying out regular check-ups Monitoring of patients at risk. The latter were surrounded by a scientific council of 6 expert pulmonologists. Biosency is the winner of the 20th i-Lab competition. I-lab is the national competition to support the creation of innovative technological companies, organized by the Ministry of Higher Education, Research and Innovation.
It rewards the best French deeptech projects. Obtaining certification is a key step in the development of Biosency because it authorizes the marketing of this first service which begins in March Biosency, Territoire Innovation winner, is participating in the first large-scale remote monitoring experiment for patients suffering from sleep apnea or COPD. For 3 and a half years, patients will be monitored remotely in order to assess the benefit of treatment integrating connected objects in these chronic respiratory diseases.
A new major step in our development has been reached with the signing of a strategic partnership with ResMed, world leader in innovative solutions for the treatment of respiratory disorders. This certification is proof of our dedication to meeting the strict standards and regulations set out under the European Medical Device Regulation and reinforces our commitment to ensuring the highest level of quality, safety and performance for our medical device, for the benefit of patients and healthcare professionals.
Biosency has reached a major milestone by obtaining definitive certification in the interoperability and security framework for digital medical devices for its remote monitoring offer dedicated to patients with respiratory failure.
